Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 31;10(4):e0124722.
doi: 10.1128/spectrum.01247-22. Epub 2022 Jul 20.

SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection

Amy J Schuh  1 , Panayampalli S Satheshkumar  1 , Stephanie Dietz  1 , Lara Bull-Otterson  1 , Myrna Charles  1 , Chris Edens  1 , Jefferson M Jones  1 , Kristina L Bajema  1 , Kristie E N Clarke  1 , L Clifford McDonald  1 , Sadhna Patel  1 , Kendra Cuffe  1 , Natalie J Thornburg  1 , Jarad Schiffer  1 , Kelly Chun  2 , Monique Bastidas  2 , Manory Fernando  2 , Christos J Petropoulos  2 , Terri Wrin  2 , Suqin Cai  2 , Dot Adcock  2 , Deborah Sesok-Pizzini  2 , Stanley Letovsky  2 , Alicia M Fry  1 , Aron J Hall  1 , Adi V Gundlapalli  1
Affiliations

SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection

Amy J Schuh et al. Microbiol Spectr. .

Abstract

Previous COVID-19 vaccine efficacy (VE) studies have estimated neutralizing and binding antibody concentrations that correlate with protection from symptomatic infection; how these estimates compare to those generated in response to SARS-CoV-2 infection is unclear. Here, we assessed quantitative neutralizing and binding antibody concentrations using standardized SARS-CoV-2 assays on 3,067 serum specimens collected during 27 July 2020 to 27 August 2020 from COVID-19-unvaccinated persons with detectable anti-SARS-CoV-2 antibodies. Neutralizing and binding antibody concentrations were severalfold lower in the unvaccinated study population compared to published concentrations at 28 days postvaccination. In this convenience sample, ~88% of neutralizing and ~63 to 86% of binding antibody concentrations met or exceeded concentrations associated with 70% COVID-19 VE against symptomatic infection; ~30% of neutralizing and 1 to 14% of binding antibody concentrations met or exceeded concentrations associated with 90% COVID-19 VE. Our study not only supports observations of infection-induced immunity and current recommendations for vaccination postinfection to maximize protection against COVID-19, but also provides a large data set of pre-COVID-19 vaccination anti-SARS-CoV-2 antibody concentrations that will serve as an important comparator in the current setting of vaccine-induced and hybrid immunity. As new SARS-CoV-2 variants emerge and displace circulating virus strains, we recommend that standardized binding antibody assays that include spike protein-based antigens be utilized to estimate antibody concentrations correlated with protection from COVID-19. These estimates will be helpful in informing public health guidance, such as the need for additional COVID-19 vaccine booster doses to prevent symptomatic infection. IMPORTANCE Although COVID-19 vaccine efficacy (VE) studies have estimated antibody concentrations that correlate with protection from COVID-19, how these estimates compare to those generated in response to SARS-CoV-2 infection is unclear. We assessed quantitative neutralizing and binding antibody concentrations using standardized assays on serum specimens collected from COVID-19-unvaccinated persons with detectable antibodies. We found that most unvaccinated persons with qualitative antibody evidence of prior infection had quantitative antibody concentrations that met or exceeded concentrations associated with 70% VE against COVID-19. However, only a small proportion had antibody concentrations that met or exceeded concentrations associated with 90% VE, suggesting that persons with prior COVID-19 would benefit from vaccination to maximize protective antibody concentrations against COVID-19.

Keywords: COVID-19; IgG; SARS-CoV-2; anti-SARS-CoV-2; antibody; correlate of protection; correlation; immune; immunity; neutralizing antibodies; protection; quantitative; standardized.

PubMed Disclaimer

Conflict of interest statement

The authors declare a conflict of interest. A.J.S., P.S.S., S.D., L.B., M.C., C.E., J.M.J., K.L.B., K.E.N.C., L.C.M., S.P., K.C., N.J.T., J.S., M.F., D.A., D.S., A.M.F., A.J.H., and A.V.G. have declared no potential conflicts of interest. K.C., M.B., M.F., C.J.P., T.W., S.C., D.A., D.S., and S.L. are/were employees of Labcorp during the study period. C.J.P. and S.L. have received grants or contracts on behalf of Labcorp-Monogram Biosciences from the United States Department of Health and Human Services/Biomedical Advanced Research and Development Authority and/or the United States Centers for Disease Control and Prevention. K.C. has a patent planned for a component of the Cov2Quant IgG Assay technology. K.C., M.B., C.J.P., T.W., S.C., D.S., and S.L. participate or have the option to participate in the Labcorp employee stock program.

Figures

FIG 1
FIG 1
SARS-CoV-2 50% neutralizing antibody titer (NT50) concentrations and anti-SARS-CoV-2 receptor binding domain (RBD) IgG concentrations for the overall convenience sample of 3,067 serum specimens collected during 27 July 2020 to 27 August 2020 with detectable anti-SARS-CoV-2 antibodies on a qualitative assay and according to sex and age category. SARS-CoV-2 NT50 concentrations in international units per milliliter (IU/mL) (A) and anti-SARS-CoV-2 RBD IgG concentrations in binding antibody units per milliliter (BAU/mL) (B) are shown. Horizontal bars represent geometric means, vertical error bars represent 95% confidence intervals, and dashed horizontal lines represent assay cutoff values for seropositivity. P values from t tests (for sex) and post hoc Tukey tests (for age class) are shown for each sex and age class comparison. Bolded P values denote statistical significance (P < 0.05). Dotted horizontal lines represent antibody concentrations associated with 70% and 90% ChAdOx1 (11) and mRNA-1273 (12) vaccine efficacy (VE). The percentage of sera with antibody concentrations that met or exceeded the concentrations represented by each of the horizontal dotted lines are shown below the charts.
FIG 2
FIG 2
Correlations between SARS-CoV-2 50% neutralizing antibody titer (NT50) concentrations in international units per milliliter (IU/mL) and anti-SARS-CoV-2 receptor binding domain (RBD) IgG concentrations in binding antibody units per milliliter (BAU/mL) for the convenience sample of 3,067 serum specimens collected during 27 July 2020 to 27 August 2020 with detectable anti-SARS-CoV-2 antibodies in a qualitative assay. (A) Overall comparison; (B) comparison by sex; (C) comparison by age class.
FIG 3
FIG 3
SARS-CoV-2 50% neutralizing antibody titer (NT50) concentrations in international units per milliliter (IU/mL) and anti-SARS-CoV-2 receptor binding domain (RBD) IgG concentrations in binding antibody units per milliliter (BAU/mL) for the overall convenience sample of 3,067 serum specimens collected during 27 July 2020 to 27 August 2020 with detectable anti-SARS-CoV-2 antibodies on a qualitative assay compared to 28 days post-COVID-19 vaccination concentrations in ChAdOx1 (11) and mRNA-1273 (12) VE study participants classified as not having COVID-19 during the follow-up period. (A) Median and interquartile range SARS-CoV-2 NT50 concentrations for the overall convenience sample compared to concentrations in VE study participants who received the ChAdOx1 vaccine and were classified as not having COVID-19 during the follow-up period. (B) Geometric mean and 95% confidence interval SARS-CoV-2 NT50 concentrations for the overall convenience sample compared to concentrations in VE study participants who received the mRNA-1273 vaccine and were classified as not having COVID-19 during the follow-up period. (C) Median and interquartile range anti-SARS-CoV-2 RBD IgG concentrations for the overall convenience sample compared to concentrations in VE study participants who received the ChAdOx1 vaccine and were classified as not having COVID-19 during the follow-up period. (D) Geometric mean and 95% CI anti-SARS-CoV-2 RBD IgG concentrations for the overall convenience sample compared to concentrations in VE study participants who received the mRNA-1273 vaccine and were classified as not having COVID-19 during the follow-up period. Horizontal bars represent medians or geometric means, and vertical error bars represent the interquartile range surrounding the median or 95% confidence intervals surrounding the geometric mean.
See this image and copyright information in PMC

References

    1. US Centers for Disease Control and Prevention. 2022. COVID-19 vaccinations in the United States. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-.... Accessed 29 March 2022.
    1. Jones JM. 6 August 2021. About One in Five Americans Remain Vaccine-Resistant. https://news.gallup.com/poll/353081/one-five-americans-remain-vaccine-re....
    1. US Centers for Disease Control and Prevention. 2021. Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine.... Accessed 5 November 2021. - PubMed
    1. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, Tostanoski LH, Yu J, Maliga Z, Nekorchuk M, Busman-Sahay K, Terry M, Wrijil LM, Ducat S, Martinez DR, Atyeo C, Fischinger S, Burke JS, Slein MD, Pessaint L, Van Ry A, Greenhouse J, Taylor T, Blade K, Cook A, Finneyfrock B, Brown R, Teow E, Velasco J, Zahn R, Wegmann F, Abbink P, Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kordana N, Li Z, Lifton MA, Mahrokhian SH, Maxfield LF, Nityanandam R, Nkolola JP, Schmidt AG, Miller AD, Baric RS, Alter G, Sorger PK, Estes JD, Andersen H, Lewis MG, Barouch DH. 2020. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369:812–817. doi:10.1126/science.abc4776. - DOI - PMC - PubMed
    1. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, Liu J, Peter L, Atyeo C, Zhu A, Bondzie EA, Dagotto G, Gebre MS, Jacob-Dolan C, Li Z, Nampanya F, Patel S, Pessaint L, Van Ry A, Blade K, Yalley-Ogunro J, Cabus M, Brown R, Cook A, Teow E, Andersen H, Lewis MG, Lauffenburger DA, Alter G, Barouch DH. 2021. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590:630–634. doi:10.1038/s41586-020-03041-6. - DOI - PMC - PubMed

Publication types

Supplementary concepts

Grants and funding